drugset
drugset / Trial / NCT00725439

An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne

NCT00725439 ↗

Phase 2 Completed 16 enrolled Stiefel, a GSK Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is looking at a new oral drug to treat acne. All patients in the study will get active drug, there is no placebo arm.

Timeline

Start
2004-09
Primary completion
2005-07
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Talarozole Small molecule 1 mg Oral

Indications

acne